Bioventus Inc (BVS)

NASD · Healthcare · Medical Devices · USA

Bioventus Inc is a small cap company (market value between $300 million and $2 billion) in the Medical Devices industry.

Bioventus is a global medical device company addressing musculoskeletal challenges through three business areas: Pain Treatments, Surgical Solutions, and Restorative Therapies. Its portfolio includes hyaluronic acid injections for knee osteoarthritis, peripheral nerve stimulation devices, ultrasonic surgical systems, and bone graft substitutes. The company serves physicians in the U.S. and international markets across office, surgical center, and hospital settings.

From its FY2025 annual report (Form 10-K)

Intrinsic value, DCF valuation, financial health and value investing analysis for the Bioventus Inc stock.

Our verdict on BVS

Undervalued: intrinsic value $21.39 per share, market price $10.60, margin of safety 50.4% (as of 2026-11-17).

Discounting its cash flows at 8.3% (average of 3 methods) values the shares at $21.39; the price of $10.60 is 50% below that value, and 79% of that value comes from beyond year five.

ETFs with the most weight in BVS

17 more funds hold it; the full list is part of the paid plan.

More on BVS

Browse

Peers in Medical Devices

All 140 Medical Devices stocks

Cheaper than BVS in Medical Devices

Is BVS undervalued or overvalued?

BVS is undervalued (as of the 2026-11-17 close). Discounting its cash flows at 8.3% (average of 3 methods) values the shares at $21.39; the price of $10.60 is 50% below that value, and 79% of that value comes from beyond year five.

What is the intrinsic value of BVS?

$21.39 per share (as of the 2026-11-17 close), against a market price of $10.60. That is a margin of safety of 50.4%. The value is the average of the 3 valuation methods that apply to this company, recomputed every night after the US close.